Xbrane has approved its deal with Alvotech that will hand over the company’s Swedish R&D facilities and in-development Cimzia (certolizumab pegol) biosimilar, as part of an extra general meeting.
Last month, the Icelandic company
Xbrane Approves Deal Giving Away Cimzia Rival To Alvotech
The Agreement Also Hands Over Xbrane’s Campus Solna Facilities To Alvotech
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
More from Deals
More from Generics Bulletin
• By
As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.
• By
With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.
• By
The Belgian value-added medicines specialist company struck two commercialization deals over its novel valacyclovir oral suspension that span three continents, marking a further milestone in the product’s development.